A Study to Evluate Efficacy and Safety of HRS-8080 Combined With Dalpiciclib in Patients With Advanced or Metastatic Breast Cancer Resistant to Adjuvant Endocrine Therapy.

The study is being conducted to evaluate the efficacy and safety of HRS-8080 combined with dalpiciclib versus fulvestrant combined with dalpiciclib in patients with locally advanced/metastatic breast cancer who had developed drug resistance to prior adjuvant endocrine therapy.

Trial Details

NCT ID
NCT07354022
Phase
PHASE3
Sponsor
Shandong Suncadia Medicine Co., Ltd.
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • HRS-8080 Tablet ; Dalpiciclib Isethionate
  • Fulvestrant injection ;Dalpiciclib Isethionate
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

  • Women aged 18 - 75 years old;
  • Eastern Cooperative Oncology Group performance status (ECOG-PS) of 0 to 1;
  • Patients with histologically confirmed locally advanced or metastatic breast cancer;
  • Patients with prior adjuvant endocrine resistance following curative-intent surgery;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →